In laboratories across the world, cancer cells have long been studied in isolation — stripped of the living context that shapes their behavior and their resistance. Researchers at Rice University have moved closer to the truth by constructing a three-dimensional bone-like scaffold that includes the immune cells, called macrophages, which naturally inhabit tumors and, paradoxically, shield cancer from the very drugs meant to destroy it. Their findings, centered on osteosarcoma, suggest that the persistent gap between promising lab results and clinical failure is not a mystery of chemistry but o
New bone cancer model reveals how immune cells shield tumors from chemotherapy
Immune cells meant to heal wounds become the tumor's shield
Mark
So the basic problem is that cancer cells in a dish don't act like cancer cells in a body. What's different?
Mimi
They're isolated. In a real tumor, cancer cells are surrounded by immune cells, blood vessels, connective tissue—a whole microenvironment sending signals. A petri dish strips all that away.
Luke
But we've known that for years. What's new about this model?
Mimi
They built a 3D scaffold that mimics bone structure and added macrophages—immune cells—into the mix. So now you're testing how the cancer cells respond not just to the drug, but to the immune environment around them.
Mark
And what did they find?
Mimi
That macrophages actually reduce how well chemotherapy works. The immune cells release wound-healing signals that protect the tumor from doxorubicin, one of the standard drugs for osteosarcoma.
Luke
How much do we know about why this happens? Is it just inflammation, or is there a specific mechanism?
Mimi
The paper shows that increased inflammation from macrophages reduces drug effectiveness. But the exact molecular pathway—that's still being worked out.
Mark
So this could change how we treat bone cancer?
Mimi
Eventually, yes. The vision is personalized medicine—testing a patient's own tumor cells and immune profile in the lab to see which drugs would actually work for them.
Luke
That's the vision. But how far away is that from clinical practice?
Mimi
Years, probably. This is a proof-of-concept study. They've shown the model works and that it reveals something real about drug resistance. Translating that into patient care is a longer road.
Mark
What about patients right now with osteosarcoma?
Mimi
This doesn't change their treatment immediately. But it opens a path toward better options down the line—drugs that target the immune cells, not just the cancer cells.
The Pulse
- Chemotherapy drugs that succeed in petri dishes routinely fail in patients, and Rice University researchers believe they now understand a key reason why: the immune cells living inside tumors are protecting the cancer.
- Macrophages — white blood cells that can make up half a tumor's mass — mistake cancer for an unhealing wound and release signals that actively reduce the effectiveness of doxorubicin, a standard bone cancer drug.
- The team engineered a 3D scaffold from synthetic polymer and gelatin to mimic real bone texture, seeding it with both osteosarcoma and immune cells to recreate the mechanical and biological environment that flat lab dishes cannot capture.
- Because osteosarcoma is rare and manifests differently in nearly every patient, researchers envision using personalized versions of these models to test which therapies would work for a specific individual's tumor biology.
- The work opens a path toward drugs that do not merely attack cancer cells but reprogram the immune cells guarding them — reframing cancer treatment as a negotiation with an entire cellular ecosystem, not a battle against a single enemy.
In laboratories across the world, cancer cells have long been studied in isolation — stripped of the living context that shapes their behavior and their resistance. Researchers at Rice University have moved closer to the truth by constructing a three-dimensional bone-like scaffold that includes the immune cells, called macrophages, which naturally inhabit tumors and, paradoxically, shield cancer from the very drugs meant to destroy it. Their findings, centered on osteosarcoma, suggest that the persistent gap between promising lab results and clinical failure is not a mystery of chemistry but of context — and that closing it may require rebuilding the tumor's entire social world before we can learn how to dismantle it.
When cancer cells are studied alone in a laboratory dish, they lie. Stripped of their cellular neighbors and chemical surroundings, they behave differently than they would inside a human body — and the drugs tested against them often reflect that fiction. Researchers at Rice University, led by bioengineering professor Antonios Mikos and doctoral researcher Letitia Chim, set out to build a more honest model: a three-dimensional scaffold made from synthetic polymer and gelatin, engineered to mimic the stiffness and texture of actual bone, and seeded with both osteosarcoma cells and the immune cells that naturally inhabit tumors.
The critical addition was the immune layer. Macrophages — a type of white blood cell — can comprise up to half of a tumor's cellular mass. In healthy tissue, they perform a vital function, releasing signals that promote wound healing. Inside a tumor, that same healing instinct becomes a liability: the macrophages treat the cancer as a wound that never closes, and their protective signals paradoxically shield tumor cells from chemotherapy. When the team tested doxorubicin, a standard drug for osteosarcoma, they found that the presence of macrophages significantly blunted its effectiveness. The immune system, designed to defend the body, was instead defending the cancer.
Osteosarcoma is both rare and deeply variable — the disease manifests differently in nearly every patient, making standardized treatment inherently limited. Chim and Mikos envision a future where these tumor models become personalized diagnostic tools, recreating a patient's own cancer cells and immune profile in the lab to identify which therapies would work best for that individual. Beyond personalization, the findings also point toward a new class of drugs designed not just to kill cancer cells, but to reprogram the macrophages protecting them — turning the immune system from an unwitting accomplice into an active ally in the fight against the disease.
When cancer cells sit alone in a laboratory dish, they lie. They behave differently than they would inside a human body, stripped of the cellular neighbors and chemical signals that shape their true nature. Researchers at Rice University recognized this fundamental problem and built something closer to the truth: a three-dimensional scaffold engineered to mimic bone structure, seeded with both osteosarcoma cells and immune cells called macrophages, designed to recreate the actual environment where tumors grow and resist treatment.
The work, published in Biomaterials, emerged from a simple observation that had troubling implications. Drugs that show promise in traditional petri dish experiments often fail to deliver the same results when tested in actual patients. The gap between the lab and the clinic suggested that something essential was missing from how researchers were modeling disease. Antonios Mikos, a bioengineering professor at Rice, and his team, led by doctoral researcher Letitia Chim, set out to close that gap by building a more honest experimental system.
The scaffolds themselves are constructed from two materials—a stiff synthetic polymer and gelatin—combined in ratios that researchers can adjust to control the overall stiffness of the fiber structure. Under a microscope, the fibers appear at a scale that cells actually recognize as three-dimensional, fundamentally different from the flat surface of a traditional dish. Cancer cells, it turns out, are sensitive to the mechanical properties of what they grow on. By mimicking the texture of actual bone, the team created a substrate that behaves more like the environment inside a patient's body.
But the real innovation was adding the next layer of complexity: the immune cells that naturally inhabit tumors. Macrophages, a type of white blood cell, can comprise up to half of a tumor's cellular mass. In healthy tissue, these cells serve a vital function, sending out signals that promote wound healing and tissue repair. Inside a tumor, however, this same healing response becomes a liability. The macrophages treat the cancer as a wound that never closes, releasing chemical signals that paradoxically protect tumor cells from harm.
When the Rice team tested doxorubicin, a standard chemotherapy drug used to treat osteosarcoma (the most common form of bone cancer), they found that the presence of macrophages and the inflammation they triggered significantly reduced the drug's effectiveness. The immune system, meant to defend the body, was instead shielding the cancer from attack. This discovery explained, at least in part, why laboratory results so often fail to translate into clinical success. The models had been missing the immune component entirely.
Osteosarcoma itself presents a particular challenge. It is rare, which means fewer patients and less research attention. It is also heterogeneous—the disease manifests differently in nearly every patient who develops it. This variability makes standardized treatment approaches inherently limited. Chim and Mikos envision a future where tumor models become personalized tools, where a patient's own cancer cells and immune profile are recreated in the laboratory to test which therapies would work best for that individual. Rather than applying a one-size-fits-all protocol, clinicians could identify targeted treatments tailored to the specific biology of each tumor.
The findings also point toward a new class of therapeutics—drugs designed not only to kill cancer cells directly but to reprogram the immune cells that protect them. By understanding how macrophages shield tumors from chemotherapy, researchers can now design interventions that either block those protective signals or flip the immune cells' allegiance, turning them into active participants in the fight against cancer. The work is funded by the National Institutes of Health and represents a shift in how the field thinks about drug development: not as a battle against cancer cells alone, but as a negotiation with the entire ecosystem that surrounds them.
Notable Quotes
Existing tumor models used to test drug performance do not mimic the actual environment in the human body closely enough.— Antonios Mikos, Rice University bioengineering professor
Tumors have sometimes been described as wounds that never heal, and that's partly due to the macrophages sending out wound-healing signals.— Letitia Chim, lead researcher
Want the full story?
Read the original at Futurity: Research News ↗
Health & Medicine